XML 29 R8.htm IDEA: XBRL DOCUMENT v3.22.2.2
Product Sales
 9 Months Ended
Sep. 30, 2022
Revenue from Contract with Customer [Abstract]  
Product Sales Product Sales
Net product sales consist of the following:
Three Months Ended
September 30,		Nine Months Ended
September 30,
(In millions)2022202120222021
EYLEA®
U.S.$1,629.4 $1,473.4 $4,768.2 $4,245.1 
Libtayo®(a)
U.S.94.7 78.4 264.5 225.5 
ROW(b)
31.0 — 31.0 — 
Praluent®
U.S.29.7 44.8 94.5 130.0 
REGEN-COV®(c)
U.S.— 676.7 — 3,530.1 
Evkeeza®
U.S.13.6 6.6 33.2 9.1 
Inmazeb®
U.S.3.0 — 3.0 — 
ARCALYST®(d)
U.S.— — — 2.2 
$1,801.4 $2,279.9 $5,194.4 $8,142.0 
(a) Prior to July 1, 2022, Regeneron recorded net product sales of Libtayo in the United States and Sanofi recorded net product sales of Libtayo outside the United States. Effective July 1, 2022, the Company began recording net product sales of Libtayo outside the United States. See Note 3 for further details.
(b) Rest of world ("ROW")
(c) Net product sales of REGEN-COV in the United States relate to product sold in connection with our agreements with the U.S. government. See Note 3 for further details.
(d) Effective April 1, 2021, Kiniksa records net product sales of ARCALYST in the United States. Previously, the Company recorded net product sales of ARCALYST in the United States.
As of September 30, 2022 and December 31, 2021, the Company had $4.268 billion and $5.059 billion, respectively, of trade accounts receivable that were recorded within Accounts receivable, net.
The Company had product sales to certain customers that accounted for more than 10% of total gross product revenue for the three and nine months ended September 30, 2022 and 2021. Sales to each of these customers as a percentage of the Company's total gross product revenue are as follows:
Three Months Ended
September 30,		Nine Months Ended
September 30,
2022202120222021
Besse Medical, a subsidiary of AmerisourceBergen Corporation
56 %40 %56 %33 %
McKesson Corporation28 %24 %29 %20 %
U.S. government— %25 %— %38 %